Acutaas Chemicals has scheduled a series of investor conferences and meetings for August 12 and 13, 2026, to engage with investors and analysts. The company’s officials will participate in one-on-one and group meetings across two locations: Singapore and Mumbai. This engagement aims to provide market participants with direct access to management for discussions regarding the company’s operations and outlook.

The schedule was disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Acutaas Chemicals emphasized that no unpublished price-sensitive information is intended to be discussed during these sessions. The company noted that the schedule remains subject to change if necessary.

Conference Schedule

The detailed itinerary for the investor interactions is as follows:

Compliance and Disclosure

Ekta Kumari Srivastava, Company Secretary & Compliance Officer, issued the intimation on August 8, 2026. The notice was submitted to the Listing Departments of both BSE Limited and the National Stock Exchange of India Limited. By adhering to the regulatory framework, Acutaas Chemicals ensures transparency in its communication with stakeholders while maintaining strict controls over sensitive data dissemination.

Investors are advised to monitor official announcements for any updates regarding the schedule or format of these meetings. The events represent standard corporate governance practices aimed at fostering investor confidence through regular dialogue.

Acutaas Chemicals reported a 70.4% year-on-year increase in net profit after tax (PAT) to ₹74.9 crore for the quarter ended June 30, 2026, driven by robust demand in its Advanced Pharmaceutical Intermediates segment and the commencement of commercial supplies from its new battery chemicals plant. Revenue from operations surged 59.1% to ₹329.7 crore, supported by strong performance in Contract Development and Manufacturing Organization (CDMO) projects and core pharmaceutical products. The company reaffirmed its full-year guidance of 25% revenue growth while maintaining stable margins, despite initial supply chain turbulence caused by geopolitical tensions in the Gulf.

The earnings call, held on July 24, 2026, was moderated by Nuvama Institutional Equities and attended by Chairman and Managing Director Naresh Patel, President of Strategy Abhishek Patel, and Chief Financial Officer Bhavin Shah. The transcript was filed with the BSE and NSE pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management highlighted that effective supply chain management mitigated raw material pressures, ensuring continuity of operations.

Financial metrics for Q1 FY27 reflect significant margin expansion. Gross profit reached ₹190.9 crore, a 73% increase compared to the same period last year, driving gross margins up by 466 basis points to 57.9%. EBITDA more than doubled to ₹113.1 crore, with margins expanding by 973 basis points to 34.3%. PAT margins improved by 151 basis points to 22.7%. The strong cash position of ₹314 crore provides ample liquidity to fund ongoing expansions without increasing leverage.

Segment Performance

The Advanced Pharmaceutical Intermediates segment remained the primary growth engine, contributing ₹292.7 crore in revenue, a 76.5% year-on-year increase. This growth was driven by both core products and new products gaining volume traction, alongside strong performance in the CDMO business. Conversely, the Specialty Chemicals segment saw revenue decline by 10.6% to ₹37 crore as the company continues to phase out commodity chemicals in favor of higher-margin specialty products. While Battery Fluid Chemicals (BFC) recovered strongly, this was offset by the planned reduction in commodity chemical sales.

Strategic Developments

Management provided updates on key strategic initiatives. The battery chemicals plant has completed trial runs and commenced commercial supply, with production expected to ramp up quarter-on-quarter. The company holds supply contracts for Vinylene Carbonate (VC) and Fluoroethylene Carbonate (FEC), with a total capacity of 4,000 metric tons. Additionally, the Indichem plant for semiconductor chemicals is ahead of schedule, with capital expenditure expected to complete by the end of Q2 FY27. Revenue from this facility is anticipated to begin in FY28.

Capital expenditure for Q1 FY27 totaled ₹56 crore, with ₹41 crore allocated to the ACL site—primarily for the battery chemical project at Jhagadia—and ₹15 crore to the Indichem site. For the full year, management indicated additional capex would be incurred for a new R&D center and land acquisition for future capacity expansion, particularly for the Pharma Intermediate business where existing plants are nearing capacity limits.

What the Numbers Show

The divergence between segment performance highlights Acutaas's strategic shift toward higher-value products. While Specialty Chemicals revenue declined due to the deliberate phase-out of low-margin commodities, the overall company margins expanded significantly. This suggests that the mix shift within the Pharmaceutical Intermediates business—specifically the growing contribution from high-margin CDMO projects—is effectively offsetting the lower-margin impact of emerging businesses like battery chemicals. The strong cash position of ₹314 crore provides ample liquidity to fund these expansions without increasing leverage.